Clinical trial

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219

Study summary

ClinicalTrials.gov

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Trastuzumab deruxtecan Normalized identity: trastuzumab deruxtecan View linked drug · Find medicine records · Find other trials using this name

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-12-30

PhasePHASE2

Conditions

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breastunresolved

Interventions

Trastuzumab deruxtecanDRUG · verified · RxNorm: trastuzumab deruxtecan

Sponsors & collaborators

AstraZenecalead sponsor

Daiichi Sankyo Co., Ltd.collaborator

Mapped research locations

SeoulSouth Korea3 BostonMassachusetts, United States2 MadridSpain2 MilanItaly2 New YorkNew York, United States1 HoustonTexas, United States1 BarcelonaSpain1 SevilleSpain1 LyonFrance1 BordeauxFrance1 NaplesItaly1 FairfaxVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04639219 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.